These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Conversion of thrombin into an anticoagulant by protein engineering. Gibbs CS; Coutré SE; Tsiang M; Li WX; Jain AK; Dunn KE; Law VS; Mao CT; Matsumura SY; Mejza SJ Nature; 1995 Nov; 378(6555):413-6. PubMed ID: 7477382 [TBL] [Abstract][Full Text] [Related]
6. A critical role for thrombin in platelet aggregation under high shear stress. Sakurai Y; Shima M; Giddings J; Takeyama M; Kasuda S; Nogami K; Nishiya K; Yoshioka A Thromb Res; 2004; 113(5):311-8. PubMed ID: 15183043 [TBL] [Abstract][Full Text] [Related]
7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442 [TBL] [Abstract][Full Text] [Related]
8. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274 [TBL] [Abstract][Full Text] [Related]
9. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Day JR; Haskard DO; Taylor KM; Landis RC Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862 [TBL] [Abstract][Full Text] [Related]
10. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. Chackalamannil S J Med Chem; 2006 Sep; 49(18):5389-403. PubMed ID: 16942011 [No Abstract] [Full Text] [Related]
11. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation. de Candia M; Liantonio F; Carotti A; De Cristofaro R; Altomare C J Med Chem; 2009 Feb; 52(4):1018-28. PubMed ID: 19193009 [TBL] [Abstract][Full Text] [Related]
12. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent. Lee S Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid. Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437 [TBL] [Abstract][Full Text] [Related]
14. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile. Kaiser B; Richter M; Hauptmann J; Markwardt F Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761 [TBL] [Abstract][Full Text] [Related]
16. A laboratory method for parallel determination of platelet aggregation and thrombin generation. Köstenberger M; Gallistl S; Cvirn G; Muntean W Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219 [TBL] [Abstract][Full Text] [Related]